0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > IgE Fc

IgE Fc

Brief Information

Name:Immunoglobulin E
Target Synonym:Immunoglobulin E
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:23
Lastest Research Phase:Approved

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Markierungen:
Nach Konjugaten:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
IGE-M52H3 Mouse Mouse IgE Fc Protein, His Tag (MALS & SPR verified)
IGE-M52H3-structure
IGE-M52H3-sds
IGE-C52H3 Cynomolgus Cynomolgus IgE Fc Protein, His Tag (MALS & SPR verified)
IGE-C52H3-structure
IGE-C52H3-sds
IGE-H52H9 Human Human IgE Fc Protein, His Tag
IGE-H52H9-structure
IGE-H52H9-sds
ACRO Quality

Part of Bioactivity data

IGE-M52H3-SPR
 IgE Fc SPR

Human Fc epsilon RI alpha, His Tag (Cat. No. FCA-H5228) immobilized on CM5 Chip can bind Mouse IgE Fc Protein, His Tag (Cat. No. IGE-M52H3) with an affinity constant of 0.391 nM as determined in a SPR assay (Biacore 8K) (QC tested).

IGE-C52H3-SPR
 IgE Fc SPR

Cynomolgus Fc epsilon RI alpha, His Tag (Cat. No. FCA-C52H9) immobilized on CM5 Chip can bind Cynomolgus IgE Fc Protein, His Tag (Cat. No. IGE-C52H3) with an affinity constant of 0.104 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

IgE

Background

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Omalizumab biosimilar (IBC Generium) GNR-044 Approved Ibc Generium Genolair Russian Federation Chronic Urticaria; Asthma Generium Pharmaceuticals 2022-02-09 Chronic Urticaria; Asthma Details
Omalizumab biosimilar (Mabtech) STI-004; CMAB007; CMAB-007 Approved Taizhou Maibo Taike Biotechnology Co Ltd 奥迈舒 Mainland China Asthma Taizhou Mabtech Pharmaceutical Co Ltd 2023-05-19 Chronic Urticaria; Allergic asthma; Asthma Details
Omalizumab GN-1560; RG-3648; IGE-025A; rhuMAb-E25; R-3648; E-25; IGE-025 Approved Novartis Pharma Ag, Genentech Inc Xolair, 茁乐 Australia Asthma; Chronic Urticaria null 2002-01-01 Pulmonary Disease, Chronic Obstructive; Job Syndrome; Asthma; Sinusitis; Urticaria; Esophagitis; Pemphigoid, Bullous; Bronchitis; Peanut Hypersensitivity; Allergic asthma; Infertility, Female; Angioedema; Dermatitis, Atopic; Mastocytosis; Hypersensitivity; Rhinitis; Gastroenteritis; Respiratory Tract Infections; Eosinophilic Esophagitis; Lupus Erythematosus, Systemic; Food Hypersensitivity; Immune System Diseases; Nose Diseases; Coronavirus Disease 2019 (COVID-19); Milk Hypersensitivity; Colonic Neoplasms; Sjogren's Syndrome; Nasal Polyps; Chronic Urticaria; Autism Spectrum Disorder; Rhinitis, Allergic, Seasonal; Anaphylaxis; Drug Hypersensitivity Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Omalizumab biosimilar (Synermore Biologics) SYN-008 Phase 3 Clinical Cspc Baike (Shandong) Biopharmaceutical Co Ltd, Synermore Biologics (Suzhou) Co Ltd Chronic Urticaria Details
Omalizumab biosimilar (Reliance Life Sciences) R-TPR-022 Phase 3 Clinical Reliance Life Sciences Asthma Details
Omalizumab biosimilar (Teva) TEV-45779 Phase 3 Clinical Teva Pharmaceutical Industries Ltd Chronic Urticaria Details
Ligelizumab QGE-031 Phase 3 Clinical Genentech Inc Chronic Urticaria; Food Hypersensitivity; Pemphigoid, Bullous; Asthma; Urticaria; Peanut Hypersensitivity; Dermatitis, Atopic; Hypersensitivity Details
Omalizumab biosimilar (BiosanaPharma) ADL-018; AVT-23; BP-001 Phase 3 Clinical BiosanaPharma BV Chronic Urticaria; Allergic asthma Details
Recombinant anti-IgE monoclonal antibody(Cspc Baike) Phase 3 Clinical Cspc Baike (Shandong) Biopharmaceutical Co Ltd Chronic Urticaria; Asthma Details
Omalizumab biosimilar (Yuanda Shuyang) SYB-507 Phase 3 Clinical Sichuan Yuanda Shuyang Pharmaceutical Co Ltd Chronic Urticaria; Allergic asthma; Asthma Details
Anti-CEmX monoclonal antibody (Fountain Biopharma) h4B12; FB-825 Phase 2 Clinical Academia Sinica Asthma; Dermatitis, Atopic Details
UB-221 UB-221 Phase 2 Clinical Chinese Academy Of Sciences Chronic Urticaria Details
Omalizumab biosimilar (Glenmark) GBR-310 Phase 2 Clinical Glenmark Pharmaceuticals Ltd Chronic Urticaria; Asthma Details
Bifidobacterium Bifidum(Sun Yat-sen University) Phase 2 Clinical Sun Yat-Sen University Carcinoma, Hepatocellular Details
LP-003 (Tianchen Biomedical) LP-003 Phase 2 Clinical Longbio Pharma (Suzhou) Co Ltd Rhinitis, Allergic, Seasonal; Chronic Urticaria; Nasal Polyps; Rhinitis, Allergic; Allergic asthma; Asthma; Sinusitis Details
ADP-101 ADP-101 Phase 2 Clinical Alladapt Immunotherapeutics Inc Food Hypersensitivity Details
Omalizumab biosimilar (Fountain BioPharma) FB-317 Phase 1 Clinical Academia Sinica Asthma; Urticaria Details
Omalizumab biosimilar(Hisun Pharma) Phase 1 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Asthma Details
Omalizumab biosimilar(Yuhan) YH-35324 Phase 1 Clinical Yuhan Corp Chronic Urticaria; Immune System Diseases; Urticaria; Hypersensitivity Details
IGNX-001 IGNX-001; IGNX001; IGX-0107 and IGX-0109 Phase 1 Clinical IgGenix Inc Peanut Hypersensitivity Details
JYB-1904 JYB-1904 Phase 1 Clinical Jiangsu Jiye Biopharmaceutical Co Ltd Allergic asthma; Urticaria; Asthma Details
Omalizumab biosimilar (Tianchen Biomedical) Phase 1 Clinical Longbio Pharma (Suzhou) Co Ltd Chronic Urticaria Details
Anti-IgE allergy vaccine (United Biomedical) Phase 1 Clinical United Biomedical Inc Hypersensitivity Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken